Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial
Autor: | H. Gelderblom, Henk-Jan Guchelaar, R. J. van der Straaten, J. Pander, Jolien Tol, C.J.A. Punt, Ninja Antonini |
---|---|
Rok vydání: | 2008 |
Předmět: | |
Zdroj: | Journal of Clinical Oncology. 26:2574-2574 |
ISSN: | 1527-7755 0732-183X |
Popis: | 2574 Background: In the CAIRO2 study the addition of Cet to the combination Cap, Ox and Bev for patients with untreated ACC is investigated. The aim of this side study is to evaluate predictive PGx... |
Databáze: | OpenAIRE |
Externí odkaz: |